Abstract
Twenty-two patients with hypertrophic obstructive cardiomyopathy were treated with the calcium inhibitor, verapamil, which was administered in a mean oral dose of 480 mg per day. After an average of 15 months of treatment (4 to 24 months), the QRS amplitude in the electrocardiogram was significantly reduced from 4.2 to 3.8 mV. Heart volume calculated from chest x-ray films in the supine position decreased significantly from 858 to 766 ml per 1.73 m2. In 10 patients, follow-up heart catheterisation showed a decrease in left ventricular muscle mass in 7 patients and a slight increase in 3 patients. Coronary artery diameter decreased in 7 patients, increased in 1, and was unchanged in 2. The reduction in coronary artery diameter is considered to be a consequence of a reduced heart muscle mass. From all available clinical data it is concluded that verapamil treatment is superior to beta-blocker therapy.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Edwards R. H., Kristinsson A., Warrell D. A., Goodwin J. F. Effects of propranolol on response to exercise in hypertrophic obstructive cardiomyopathy. Br Heart J. 1970 Mar;32(2):219–225. doi: 10.1136/hrt.32.2.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Goodwin J. F. Congestive and hypertrophic cardiomyopathies. A decade of study. Lancet. 1970 Apr 11;1(7650):732–739. [PubMed] [Google Scholar]
- Hubner P. J., Ziady G. M., Lane G. K., Hardarson T., Scales B., Oakley C. M., Goodwin J. F. Double-blind trial of propranolol and practolol in hypertrophic cardiomyopathy. Br Heart J. 1973 Nov;35(11):1116–1123. doi: 10.1136/hrt.35.11.1116. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kaltenbach M., Hopf R., Keller M. Calciumantagonistische Therapie bei hypertroph-obstruktiver Kardiomyopathie. Dtsch Med Wochenschr. 1976 Aug 27;101(35):1284–1287. doi: 10.1055/s-0028-1104257. [DOI] [PubMed] [Google Scholar]
- Kaltenbach M. Medikamentöse Therapie der koronaren Herzkrankheit. Arzneimittelforschung. 1977;27(3A):703–707. [PubMed] [Google Scholar]
- Kaltenbach M., Schulz W. Kineangiographische Bestimmung von Ventrikelvolumina mit Rechnerhilfe. Dtsch Med Wochenschr. 1975 Mar 21;100(12):590–593. doi: 10.1055/s-0028-1106262. [DOI] [PubMed] [Google Scholar]
- Kober G., Spahn G., Becker H. J., Kaltenbach M. Weite und Querschnittsfläche der grossen epikardialen Koronararterien bei Herzmuskelhypertrophie. Z Kardiol. 1974 Apr;63(4):297–310. [PubMed] [Google Scholar]
- Loogen F., Krelhaus W., Kuhn H. Verlaufsbeobachtungen der hypertrophischen obstruktiven Myokardiopathie (HOCM) Z Kardiol. 1976 Jun;65(6):511–521. [PubMed] [Google Scholar]
- Morrow A. G., Reitz B. A., Epstein S. E., Henry W. L., Conkle D. M., Itscoitz S. B., Redwood D. R. Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. Circulation. 1975 Jul;52(1):88–102. doi: 10.1161/01.cir.52.1.88. [DOI] [PubMed] [Google Scholar]
- Rothlin M., Arbenz U., Krayenbühl H. P., Turina J., Senning A. Spätresultate nach Operationen bei muskulärer subvalvulärer Aortenstenose. Z Kardiol. 1976 Jun;65(6):501–510. [PubMed] [Google Scholar]
- Stenson R. E., Flamm M. D., Jr, Harrison D. C., Hancock E. W. Hypertrophic subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy. Am J Cardiol. 1973 Jun;31(6):763–773. doi: 10.1016/0002-9149(73)90012-x. [DOI] [PubMed] [Google Scholar]
- Wrogemann K., Pena S. D. Mitochondrial calcium overload: A general mechanism for cell-necrosis in muscle diseases. Lancet. 1976 Mar 27;1(7961):672–674. doi: 10.1016/s0140-6736(76)92781-1. [DOI] [PubMed] [Google Scholar]